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aBstraCt
This is a case series of patients suffering from neurotrophic keratopathy. The main categorisation of the disease is dis­
cussed as well as the management that should be followed on each stage. Several cases of patients with neurotrophic 
keratopathy are analysed and the treatment (different on every patient) of them is presented. Newer substances that 
are beginning to be used in the treatment of neurotrophic keratopathy are discussed as well.
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introduCtion
Neurotrophic keratopathy is a degenerative dis­
ease that is characterised by reduction of corneal 
sensitivity. In neurotrophic keratopathy, the corneal 
innervation that is procured to the cornea by the 
trigeminal nerve is impaired. Neurotrophic kerato­
pathy is estimated to affect less than 50/100,000 in­
dividuals [1]. 
Every condition, ocular or systemic, that alters 
corneal sensory innervation (from the cornea itself 
to the trigeminal nerve) can cause neurotrophic 
keratopathy. Some of the most common conditions 
that can lead to neurotrophic keratopathy are herpes 
keratitis (simplex and zoster), contact lens overuse, 
topical anaesthetic abuse, chemical and physical 
burns, topical drug toxicity, and corneal and ocular 
surgery. 
When it comes to corneal surgery, there have 
been studies [2, 3] indicating that both Photore­
fractive Keratectomy (PRK) and laser in situ ker­
atomileusis (LASIK) can potentially cause nerve 
damage. However, the chances of something like 
this happening are higher [4, 5] in LASIK surgery. 
Deep anterior lamellar keratoplasty [6] (DALK) 
and penetrating keratoplasty (PK) can also cause 
a degree of corneal insensitivity. In patients with 
keratoconus [7], who have undergone corneal col­
lagen crosslinking, a reduction of corneal sensitivity 
occurs as well.
Laser for the treatment of proliferative diabet­
ic retinopathy has also been reported [8] to cause 
neurotrophic keratopathy. Vitrectomy (for retinal 
detachment) and photocoagulation to treat diabetic 
retinopathy have been reported [9] to cause neu­
rotrophic keratopathy, as well. Also, neurosurgical 
procedures [10] or trauma damaging the fifth cra­
nial nerve, intracranial tumours, multiple sclerosis, 
aneurisms, and stroke can cause neurotrophic ker­
atitis. Diabetes, vitamin A deficiency, and leprosy 
have also been linked [10] to neurotrophic kerato­
pathy.
During clinical examination, many histological 
alterations may be observed. Thinning or disruption 
of the epithelial layer, swelling of the epithelial cells, 
disorganisation of Bowman’s membrane, stromal 
melting, or scarring and neovascularisation are sev­
eral of them. Conjunctiva is usually also involved 
with the reduction in the density of goblet cells.
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The highly concerning thing about neurotroph­
ic keratopathy is that patients usually do not seek 
medical opinion, due to the lack of sensitivity on 
the cornea, thus the lack of ocular surface symp­
toms, and the disease progresses until they do, 
months or maybe years after its first manifestation. 
Starting the clinical evaluation, the physician 
should evaluate corneal sensitivity, when neuro­
trophic keratopathy is suspected. Subsequently, cor­
neal staining with fluorescein should be performed 
in order to check for epithelial deficits. A Schirm­
er test could also be useful in order to determine 
whether the tear production has been compromised 
due to reduction of corneal sensitivity. Finally, in 
order to rule out any chance of infection, corneal 
culture should be performed.
Based on its symptoms, neurotrophic keratopa­
thy can be categorised in three stages, known as the 
“Mackie classification” [11]:
Stage 1: this stage is manifested by hyperplasia 
or irregularity of the corneal epithelium that can 
evolve to punctate keratopathy, corneal oedema, 
stromal scarring, and neovascularisation.
Stage 2: this stage is presented with recurrent 
and persistent epithelial defects, most commonly 
in the superior half of the cornea. These defects are 
usually oval­shaped and their margins are smooth 
and rolled due to the impaired epithelial healing.
Stage 3: in this stage, there is involvement of the 
stroma, which leads to corneal ulcer, melting, and 
corneal perforation.
When managing neurotrophic keratopathy, the 
main purpose is to promote corneal healing without 
any complications. Topical non­steroidal anti­in­
flammatory drugs (NSAIDs) [12] should be avoid­
ed because they do not show any improvement in 
patients with neurotrophic keratopathy and they 
can further decrease the sensitivity of the cornea. 
The management in stage 1 of the disease, where 
punctate keratopathy is clinically observed, is with 
frequent application of preservative­free artificial 
tears and lubricant ointments. The main purpose is 
to improve the quality of the epithelium and avoid 
epithelial breakdown. In cases where punctate kera­
topathy is persistent, autologous serum [13, 14] can 
be used, as well as a therapeutic soft contact lens. 
In stage 2, the main purpose of management is 
to heal the persistent epithelial defects and prevent 
the formation of corneal ulcers. The treatment usu­
ally includes plenty of artificial tears and lubricant 
ointments, autologous serum use, amniotic mem­
brane [14] graft, or tarsorrhaphy, if needed, in order 
to manage the epithelial defects. Because the epithe­
lium is open, antibiotic drops can be prescribed in 
order to prevent infections [1]. 
In stage 3, the treatment is focused on the pre­
vention of corneal perforation. In addition to the 
treatment used for stages 1 and 2, in stage 3 oral dox­
ycycline, medroxyprogesterone, can be prescribed if 
stromal melting is observed [15]. A ReGeneraT­
ing Agent (RGTA) polymer [16] eye drop has also 
proven to be successful in treating persistent neu­
rotrophic ulcers. Similarly, a recombinant version 
of human nerve growth factor (Cenegermin) [17] 
has been proven to restore the normal healing pro­
cess of the eye and repair corneal damage for pa­
tients with moderate to severe neurotrophic kera­
topathy and has recently been granted approval for 
use in Europe [17].
If, despite all efforts, perforation of the cornea 
occurs, the treatment varies and depends on its size. 
If it is small, cyanoacrylate glue can be applied, 
along with a soft contact lens. If the perforation 
is larger, a conjunctival flap procedure can be per­
formed or even a lamellar keratoplasty, depending 
on the severity of the case.
Case reports
These are the case reports, presenting several dif­
ferent patients with neurotrophic keratitis and the 
pattern we chose to treat them.
patient 1
The first patient was male, 66 years old. He was 
diagnosed with Sjögren’s syndrome and severe acne 
rosacea that intensified the severe blepharitis he al­
ready had. The patient had a history of recurrent 
neurotrophic ulcers in both eyes. The patient was 
thoroughly examined by Dr Mallias (with slit lamp 
and anterior optical coherence tomography [OCT] 
as shown in Figures 1 and 2). He was diagnosed 
with keratoconjunctivitis sicca on the right eye and 
a sterile corneal ulcer on the left eye (Fig. 1), and his 
best corrected visual acuity (BCVA) was 20/30 in 
the right eye and 20/200 in the left eye. 
The patient was treated with ample artificial 
tears and an antibiotic (preventively), and a contact 
lens was placed. After three days the patient felt 
slightly better and the contact lens was removed, 
but he returned a few days later complaining of pain 
and severe loss of visual acuity. The slit lamp exam­
ination revealed corneal perforation and reflux of 
blood of Schlemm’s canal due to hypotony (Fig. 2).
Ioannis Mallias et al., Neurotrophic keratopathy
93www.journals.viamedica.pl/ophthalmology_journal
Figure 1. Slit lamp photo from the ulcer of the left eye of the first patient
Figure 2. The left eye of the first patient with corneal perforation
Dr Mallias then proceeded with a conjunctival 
flap procedure and, after two weeks, a successful 
penetrating keratoplasty procedure (Fig. 3).
patient 2 
The second patient was female, 64 years old, di­
agnosed with biopsy­proven ocular cicatricial pem­
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Figure 3. The left eye of the first patient after the penetrating keratoplasty
Figure 4. The left eye of the second patient. A large epithelial defect is observed. There is also a large area of opacification of the cornea, 
and in the centre there is a small area of descemetocele through which she was able to see 20/200
phigoid. Her BCVA was 20/32 in the right eye and 
20/200 in the left eye (Fig. 4).
 She underwent an emergency penetrating kera­
toplasty (Fig. 5) of the left eye due to eminent risk 
of corneal perforation. 
The patient developed a non­healing epithelial 
defect five months after penetrating keratoplasty in 
her left eye (Fig. 6). Artificial tears and a bandage 
soft contact lens were applied, and oral doxycycline 
was prescribed.
Despite the treatment the epithelial defect expand­
ed and covered more than half of the corneal surface 
(Fig. 7). Cortical steroids were discontinued and oral 
valacyclovir was initiated at 500 mg twice a day. 
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Figure 6. Epithelial defect over the corneal graft five months after the penetrating keratoplasty. Right image shows the epithelial defect 
stained with fluorescein. Left image shows the defect with cobalt blue light
Figure 5. First postoperative day after a penetrating keratoplasty in Patient 2. There is still mild corneal oedema but good graft apposition 
to the host cornea with 16 interrupted sutures
Despite the change of medical treatment, epi­
thelialisation was not achieved. At that point, the 
decision to start the patient on RGTA polymer eye 
drop was made. The dosage was one drop every 
other day. Several days after treatment initiation, 
the epithelium healed and the patient’s visual acuity 
improved significantly (Fig. 8).
patient 3
The third patient was female, 87 years old. She 
complained about lacrimation and severe pain in 
her right eye. Her BCVA was 20/200 for the right 
eye and 20/25 for the left eye. Slit lamp and OCT 
examination revealed corneal melt with a small de­
scemetocele (area of the cornea with total melt of 
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Figure 7. Expanded epithelial defect after treatment initiation
Figure 8. A gradual decrease of the epithelial defect is observed after the initiation of treatment with RGTA polymer drops
the corneal stroma where only Descemet’s mem­
brane is intact) on the right eye (Figs. 9 and 10). 
Dr Mallias then proceeded to treat with His­
toacryl glue (Figs. 11, 12) and a bandage soft con­
tact lens. The patient was instructed to instil ofloxa­
cin four times per day and preservative free artificial 
tears every two hours. The use of topical corticoster­
oids is contraindicated in such cases.
The Histoacryl glue remains on the cornea until 
healing is achieved. Then the glue usually falls out 
by itself
disCussion
Neurotrophic keratopathy is a complicated disease 
and should be treated carefully. Patients should be 
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Figure 9. Corneal melt with a small descemetocele in the centre
Figure 10. OCT image of the right eye of the third patient before application of Histoacryl glue
Figure 11. OCT image after the Histoacryl glue placement
closely monitored due to the lack of corneal sensitiv­
ity. In order to make the diagnosis of neurotrophic 
keratopathy, corneal sensation should be evaluated. 
To test for corneal sensation there are qualitative and 
quantitative methods [18]. The most commonly used 
method in clinical practice, which is qualitative in na­
ture, is the use of a cotton­tipped applicator. A wisp of 
the cotton­tipped applicator is used to compare sen­
sation in each eye. It is recommended to approach the 
patient from the side and test all four quadrants. The 
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Figure 12. The right eye of the third patient after the Histoacryl glue placement
sensation should be recorded in each location as: nor­
mal, reduced, or absent. Topical anaesthetics should 
not be used prior to testing corneal sensation. Cor­
neal esthesiometers could be used as well, such as the 
Handheld Cochet­Bonnet esthesiometer [18]. 
Artificial tears should be used frequently in order 
to smooth out the cornea in all the stages of the dis­
ease, and patients should be advised to be extra care­
ful to avoid infections because the corneal epithelium 
might be compromised. Even after treating the cur­
rent symptoms, patients should be extra careful and 
pay frequent visits to the ophthalmologist in order 
to make sure that the ocular surface remains healed.
Due to the nature of the disease, it is difficult to man­
age it with drugs because the preservatives that exist in 
them cause more harm than good on the ocular surface. 
This is the reason why scientists came up with the ReGen­
eraTing Agent (RGTA) eye drop and the recombinant 
version of human nerve growth factor (Cenegermin). 
Both of these substances promote epithelial healing. 
RGTA [19] acts by playing the role of glycos­
aminoglycan, more specifically, heparin sulphate. 
The absence of glycosaminoglycan is associated with 
degradation of the extracellular matrix, which can 
result in corneal thinning, non­healing epithelial 
defects, and inflammation. The RGTA agents restore 
the balance of matrix proteins and cytokines that 
are normally bound to heparin sulphate and ensure 
equilibrium in the corneal microenvironment. This 
prevents degradation of extracellular matrix proteins, 
and promotes stromal and, subsequently, epithelial 
healing. Cenegermin [17] or recombinant human 
nerve growth factor as mentioned above is an artifi­
cial form of a naturally occurring signalling protein, 
nerve growth factor (NGF). It aims to improve nerve 
function in the cornea and stimulate healing as well 
as bring back some of the lost sensation of the cor­
nea. RGTA agents have been further investigated 
and used in dealing with neurotrophic keratopathy. 
On the other hand, Cenegermin has recently been 
granted approval for use in Europe, thus the lack 
of published studies involving it. However, both 
substances promote epithelial healing to a reasonable 
degree. What would really be interesting is a study 
comparing these two agents in the treatment of neu­
rotrophic keratopathy, in order to find out which 
substance is of greater benefit for these patients.
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